Stability of Oxandrolone in Medium-Chain Triglyceride Oil and Pharmacokinetics Following Buccal Administration of the Extemporaneous Formulation in Neonates and Adults

Stability of Oxandrolone in Medium-Chain Triglyceride Oil and Pharmacokinetics Following Buccal Administration of the Extemporaneous Formulation in Neonates and Adults / Matthew W. Linakis, Joseph E. Rower, Susan Sorenson, Christopher A. Reilly, Linda M. Lambert, Richard V. Williams, Phillip T. Burch. - (Journal of Pediatric Pharmacology and Therapeutics 25 (2020) 3 (1 April); p. 220-227)

  • PMID: 32265605
  • PMCID: PMC7134583
  • DOI: 10.5863/1551-6776-25.3.220


Abstract

Objectives: Growth failure following surgical palliation of complex congenital heart defects (CHDs) is a prognosticator of poor outcomes. Many strategies for improving weight gain have been implemented in this population, with limited success. We recently described the potential of the anabolic steroid oxandrolone to improve weight gain following surgical repair of CHD when administered via a medium-chain triglyceride (MCT) oil suspension to the buccal mucosa. The current study evaluates the stability of oxandrolone in the MCT oil formulation, as well as the pharmacokinetics of oxandrolone when administered via buccal mucosa in both neonates and adults.

Methods: Stability was assessed by long-term storage of the preparation 1) at ambient conditions and 2) under photodegradative conditions for 3 days. Neonatal pharmacokinetic parameters were determined in a cohort of neonates following surgical CHD repair, whereas adult pharmacokinetics parameters were collected as part of a prospective study to evaluate the relative bioavailability of the oxandrolone in MCT oil formulation.

Results: We found that oxandrolone was stable in the MCT oil formulation for at least 1 month, although exposure to light hastened drug degradation. Both neonatal and adult oxandrolone pharmacokinetics were variable; however, oxandrolone in MCT oil was relatively well absorbed through the buccal mucosa (mean bioavailability = 62.5%).

Conclusions: These data suggest that the variability in oxandrolone exposures is inherent to the drug, and not the formulation or route of administration. Combined, these data support further study of this novel oxandrolone in MCT oil formulation and its impact on growth following complex surgical repair of CHD in neonates.

Original document

Parameters

Science
Study
Date
1 April 2020
People
Burch, Phillip T.
Lambert, Linda M.
Linakis, Matthew W.
Reilly, Christopher A.
Rower, Joseph E.
Sorenson, Susan
Williams, Richard V.
Country
United States of America
Language
English
Other organisations
Cook Children's Medical Center
University of Utah School of Medicine
Doping classes
S1. Anabolic Agents
Substances
Oxandrolone
Document category
Scientific article
Document type
Pdf file
Date generated
14 April 2021
Date of last modification
15 April 2021
Category
  • Legal Source
  • Education
  • Science
  • Statistics
  • History
Country & language
  • Country
  • Language
Other filters
  • ADRV
  • Legal Terms
  • Sport/IFs
  • Other organisations
  • Laboratories
  • Analytical aspects
  • Doping classes
  • Substances
  • Medical terms
  • Various
  • Version
  • Document category
  • Document type
Publication period
Origin